Literature DB >> 24111932

Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma.

Roman Hajek1, Samuel A Okubote, Hana Svachova.   

Abstract

Multiple myeloma (MM) is a haematological malignancy characterized by the accumulation of clonal plasma cells (PCs) in the bone marrow (BM). Although novel therapeutic strategies have prolonged survival of patients, the disease remains difficult to treat with a high risk of relapse. The failure of therapy is thought to be associated with a persistent population of the so-called MM stem cells or myeloma initiating cells (MIC) that exhibit tumour-initiating potential, self-renewal and resistance to chemotherapy. However, the population responsible for the origin and sustainability of tumour mass has not been clearly characterized so far. This review summarizes current myeloma stem cell concepts and suggests that high phenotypic and intra-clonal heterogeneity, together with plasticity potential of MM might be other contributing factors explaining discrepancies among particular concepts and contributing to the treatment failure.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  malignant plasma cells; multiple myeloma; myeloma stem cells; plasticity; precursor B cells

Mesh:

Substances:

Year:  2013        PMID: 24111932     DOI: 10.1111/bjh.12563

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  45 in total

Review 1.  Chimeric antigen receptor T-cell therapy for multiple myeloma.

Authors:  Naoki Hosen
Journal:  Int J Hematol       Date:  2020-01-25       Impact factor: 2.490

2.  Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions.

Authors:  Jianguo Wen; Wenjing Tao; Isere Kuiatse; Pei Lin; Yongdong Feng; Richard J Jones; Robert Z Orlowski; Youli Zu
Journal:  Int J Cancer       Date:  2014-07-23       Impact factor: 7.396

3.  Emerging immune targets for the treatment of multiple myeloma.

Authors:  Atif Sohail; Adeela Mushtaq; Ahmad Iftikhar; Zabih Warraich; Sandra E Kurtin; Pavan Tenneti; Ali McBride; Faiz Anwer
Journal:  Immunotherapy       Date:  2018-02-01       Impact factor: 4.196

Review 4.  Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies.

Authors:  Antonia Rotolo; Anastasios Karadimitris; Marco Ruella
Journal:  Leuk Lymphoma       Date:  2017-11-22

5.  Assessment of haematopoietic progenitor cell counting with the Sysmex® XN-1000 to guide timing of apheresis of peripheral blood stem cells.

Authors:  Francesco Dima; Erika Barison; Martina Midolo; Fabio Benedetti; Giuseppe Lippi
Journal:  Blood Transfus       Date:  2019-07-25       Impact factor: 3.443

6.  Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.

Authors:  Alfred L Garfall; Marcela V Maus; Wei-Ting Hwang; Simon F Lacey; Yolanda D Mahnke; J Joseph Melenhorst; Zhaohui Zheng; Dan T Vogl; Adam D Cohen; Brendan M Weiss; Karen Dengel; Naseem D S Kerr; Adam Bagg; Bruce L Levine; Carl H June; Edward A Stadtmauer
Journal:  N Engl J Med       Date:  2015-09-10       Impact factor: 91.245

Review 7.  Chimeric antigen receptor T-cell therapies for multiple myeloma.

Authors:  Lekha Mikkilineni; James N Kochenderfer
Journal:  Blood       Date:  2017-09-19       Impact factor: 22.113

Review 8.  Development of CAR-T cell therapies for multiple myeloma.

Authors:  Nico Gagelmann; Kristoffer Riecken; Christine Wolschke; Carolina Berger; Francis A Ayuk; Boris Fehse; Nicolaus Kröger
Journal:  Leukemia       Date:  2020-06-22       Impact factor: 11.528

9.  A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma.

Authors:  A Dispenzieri; A D'Souza; M A Gertz; K Laumann; G Wiseman; M Q Lacy; B LaPlant; F Buadi; S R Hayman; S K Kumar; D Dingli; W J Hogan; S M Ansell; D A Gastineau; D J Inwards; I N Micallef; L F Porrata; P B Johnston; M R Litzow; T E Witzig
Journal:  Bone Marrow Transplant       Date:  2017-09-04       Impact factor: 5.483

10.  Lenalidomide after stem-cell transplantation for multiple myeloma: a meta-analysis of randomized controlled trials.

Authors:  Minjie Gao; Lu Gao; Guang Yang; Yi Tao; Van S Tompkins; Xiaosong Wu; Hongwei Xu; Fenghuang Zhan; Jumei Shi
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.